Show simple item record

dc.contributor.authorSlevin, Nicholas J
dc.contributor.authorCollins, Conor D
dc.contributor.authorHastings, David L
dc.contributor.authorWaller, M L
dc.contributor.authorJohnson, Richard J
dc.contributor.authorCowan, Richard A
dc.contributor.authorBirzgalis, Andrew R
dc.contributor.authorFarrington, William T
dc.contributor.authorSwindell, Ric
dc.date.accessioned2009-12-14T12:37:35Z
dc.date.available2009-12-14T12:37:35Z
dc.date.issued1999-06
dc.identifier.citationThe diagnostic value of positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (18F-FDG) in head and neck cancer. 1999, 113 (6):548-54 J Laryngol Otolen
dc.identifier.issn0022-2151
dc.identifier.pmid10605586
dc.identifier.urihttp://hdl.handle.net/10541/87847
dc.description.abstractPositron emission tomography (PET) scanning has recently been introduced into clinical practice but its usefulness in the management of head and neck cancer is not well defined. The aim of this prospective preliminary study was to examine the clinical value of fluorodeoxyglucose (FDG)--PET in patients with head and neck cancer treated by radiotherapy with surgery in reserve by (i) relating quantitative uptake of isotope to tumour type and histological grade and (ii) comparing the imaging findings of PET and magnetic resonance imaging (MRI) in post-radiotherapy assessment of tumour response. Twenty-one patients had pre-treatment PET and MRI scans and these were repeated four and eight months after treatment if there was no clinical relapse. Pre-treatment uptake of FDG using tumour to cerebellar ratio parameters was significantly related to the histological grade of squamous cancer (p = 0.04) but not to tumour type. Discordance of post-treatment PET/MRI findings in one case indicates a possible role for PET in the early detection of tumour recurrence. Other potential uses of PET scanning in the management of head and neck cancer are discussed.
dc.language.isoenen
dc.subjectHead and Neck Canceren
dc.subjectLaryngeal Canceren
dc.subjectNose Canceren
dc.subjectTonsillar Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshCarcinoma, Squamous Cell
dc.subject.meshFemale
dc.subject.meshFluorodeoxyglucose F18
dc.subject.meshHead and Neck Neoplasms
dc.subject.meshHumans
dc.subject.meshLaryngeal Neoplasms
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNose Neoplasms
dc.subject.meshPilot Projects
dc.subject.meshPredictive Value of Tests
dc.subject.meshProspective Studies
dc.subject.meshRadiopharmaceuticals
dc.subject.meshTomography, Emission-Computed
dc.subject.meshTonsillar Neoplasms
dc.titleThe diagnostic value of positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (18F-FDG) in head and neck cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalThe Journal of Laryngology and Otologyen
html.description.abstractPositron emission tomography (PET) scanning has recently been introduced into clinical practice but its usefulness in the management of head and neck cancer is not well defined. The aim of this prospective preliminary study was to examine the clinical value of fluorodeoxyglucose (FDG)--PET in patients with head and neck cancer treated by radiotherapy with surgery in reserve by (i) relating quantitative uptake of isotope to tumour type and histological grade and (ii) comparing the imaging findings of PET and magnetic resonance imaging (MRI) in post-radiotherapy assessment of tumour response. Twenty-one patients had pre-treatment PET and MRI scans and these were repeated four and eight months after treatment if there was no clinical relapse. Pre-treatment uptake of FDG using tumour to cerebellar ratio parameters was significantly related to the histological grade of squamous cancer (p = 0.04) but not to tumour type. Discordance of post-treatment PET/MRI findings in one case indicates a possible role for PET in the early detection of tumour recurrence. Other potential uses of PET scanning in the management of head and neck cancer are discussed.


This item appears in the following Collection(s)

Show simple item record